



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application Of:

VOGELSTEIN *et al.*

Serial No.: 09/815,340

Filed: March 23, 2001

)  
) Group Art Unit: 1642  
)  
) Examiner: K. Canella  
)  
) Docket No. 01107.00074  
)

RECEIVED

NOV 01 2002

TECH CENTER 1600/2900

For: SECURIN IS REQUIRED FOR CHROMOSOMAL STABILITY IN HUMAN CELLS

**RESPONSE TO FINAL OFFICE ACTION**

Assistant Director of Patents  
Washington, D.C. 20231

Dear Sir:

Sir:

*Ok to enter - KAC*

#  
10/45  
KS  
11-702

This amendment is filed in response to the final Office Action mailed July 30, 2002.

Claims 1-23 are pending in the application. Claims 10-18 and 23 are indicated as allowed.

Claims 1-9 and 19-22 stand rejected. We believe no fee is due in connection with this response.

If any fee is due, please charge our Deposit Account No. 19-0733.

**REMARKS**

**The Invention**

The invention is based on the discovery that homozygous securin-defective cells fail to separate their metaphase chromosomes appropriately, and thus exhibit aneuploidy. An isolated and purified homozygous securin-defective human cell line is the subject of claims 1-4. A pair of isogenic mammalian cell lines is the subject of claims 5-9 and 19-22. A first cell line of the pair is homozygous securin-defective and a second cell line of the pair is securin-proficient. Such cell lines can be used to screen compounds to identify potential anti-cancer agents. See